XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2023
USD ($)
Reporting_Unit
Segment
$ / shares
shares
Dec. 31, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Summary Of Significant Accounting Policies [Line Items]      
Cash, cash equivalents and restricted cash, maturity period three months or less    
Number of operating business segments | Segment 1    
Number of reporting units | Reporting_Unit 1    
Impairment charge $ 0 $ 48,648,000  
Impairments of long-lived assets 0 0  
Goodwill $ 0 $ 0 $ 48,648,000
Basic weighted average shares outstanding | shares 24,619,197 14,285,254  
Warrants exercise price | $ / shares $ 0.001    
Tax benefit $ 0    
Income tax examination, likelihood of settlement, description The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.    
Income tax examination, likelihood of settlement, percentage 50.00%    
Common and Preferred Warrants Outstanding [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Basic weighted average shares outstanding | shares 5,776,270 509,117  
Anelixis [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Impairment charge   $ 48,600,000  
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.      
Summary Of Significant Accounting Policies [Line Items]      
Ownership interest percentage 100.00%    
Otic Pharma, Inc. [Member]      
Summary Of Significant Accounting Policies [Line Items]      
Ownership interest percentage 100.00%